title: Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994.
abstract: The prevalence and risk factors for acquisition of human T-cell lymphotropic virus type I and II (HTLV-I and II) were investigated in a prospective study of 913 injecting drug users (IDUs) in Stockholm in 1994. Epidemiologic data were recorded, and blood samples were tested for antibodies against HTLV-I and HTLV-II; human immunodeficiency virus (HIV) types 1 and 2; and hepatitis A (HAV), B (HBV), C (HCV), and D (HDV). Positive serologic results for HTLV were confirmed by Western blot (WB) and polymerase chain reaction (PCR). Of the 905 participants with conclusive HTLV-II status, 29 (3.2%) were HTLV-II positive, and all but three were of Nordic descent. None was HTLV-I infected. One person was infected as early as 1981, before HIV had reached the IDU population in Sweden. The prevalence of HTLV-II infection was 12% among HIV-1-seropositive and 1.8% among HIV-1-seronegative participants. The overall seroprevalences were 14% for HIV-1, 0% for HIV-2, 41% for HAV, 75% for HBV, 92% for HCV, and 8% for HDV. Although amphetamine has been the main injecting drug in Sweden for several decades, heroin abuse combined with a debut of injecting drugs before 1975 was identified as the most important risk factor associated with HTLV-II infection. HAV and HIV seropositivity were also independent risk factors.
authors.affiliation: Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Krook
authors.forename: J
authors.initials: J
authors.lastname: Albert
authors.forename: S
authors.initials: S
authors.lastname: Andersson
authors.forename: G
authors.initials: G
authors.lastname: Biberfeld
authors.forename: J
authors.initials: J
authors.lastname: Blomberg
authors.forename: I
authors.initials: I
authors.lastname: Eklund
authors.forename: A
authors.initials: A
authors.lastname: Engström
authors.forename: I
authors.initials: I
authors.lastname: Julander
authors.forename: K
authors.initials: K
authors.lastname: Käll
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: P
authors.initials: P
authors.lastname: Stendahl
authors.forename: J
authors.initials: J
authors.lastname: Struve
authors.forename: A
authors.initials: A
authors.lastname: Sönnerborg
mesh_terms: D000328:Adult; D000367:Age Factors; D005260:Female; D006679:HIV Seropositivity / Q000150:complications / Q000453:epidemiology; D015490:HTLV-I Infections / Q000453:epidemiology; D015482:HTLV-II Antibodies / Q000097:blood; D015491:HTLV-II Infections / Q000150:complications / Q000453:epidemiology*; D006506:Hepatitis A / Q000150:complications / Q000453:epidemiology; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000453:epidemiology; D006801:Humans; D008297:Male; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications*; D013548:Sweden / Q000453:epidemiology
chemical_list: D015482:HTLV-II Antibodies